

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from December 2015

For further details see *PACE Bulletin* Volume 10 No 1 (January 2016)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Apixaban (Eliquis) 2.5mg tablet (BMS/Pfizer)	For the prevention of venous thromboembolism following elective hip or knee replacement surgery.	RED Complete course provided from within ULH Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Apixaban (Eliquis) 2.5mg and 5mg tablet (BMS/Pfizer)	For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one risk factor.	GREEN subject to criteria. Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Apixaban (Eliquis) 2.5mg tablet (BMS/Pfizer)	For the treatment of DVT and PE and for the prevention of recurrent DVT and PE in adults.	GREEN subject to criteria. Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Dabigatran (Pradaxa) 75mg and 110mg capsules (Boehringer Ingelheim)	For the prevention of venous thromboembolism following elective hip or knee replacement surgery.	RED Complete course provided from within ULH Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Dabigatran (Pradaxa) 150mg capsules (Boehringer Ingelheim)	For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one risk factor.	GREEN subject to criteria. Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication
Dabigatran (Pradaxa) 110mg and 150mg capsules (Boehringer Ingelheim)	For the treatment of DVT and PE and for the prevention of recurrent DVT and PE in adults.	GREEN subject to criteria. Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Edoxaban (Lixiana) 60mg tablets (Dalichi Sankyo)	For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one risk factor.	RED-RED pending NICE and PACEF approval. Approved for inclusion in Lincolnshire Joint Formulary for this indication.
Edoxaban (Lixiana) 60mg tablets (Dalichi Sankyo)	For the treatment of DVT and PE and for the prevention of recurrent DVT and PE in adults.	GREEN subject to criteria. Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Rivaroxaban (Xarelto) tablets 2.5mg	For use in combination with aspirin plus clopidogrel or aspirin alone for prevention of atherothrombotic events after acute coronary syndrome s in patients with elevated cardiac biomarkers.	GREEN Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.

Rivaroxaban (Xarelto) tablets 15mg and 20mg	For the treatment of DVT and PE and for the prevention of recurrent DVT and PE in adults.	GREEN subject to criteria. Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Rivaroxaban (Xarelto) tablets 10mg	For the prevention of venous thromboembolism in patients undergoing hip or knee replacement surgery	RED Complete course provided from within ULH Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.
Rivaroxaban (Xarelto) tablets 20mg	For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one risk factor	GREEN subject to criteria Approved for inclusion in Lincolnshire Joint Formulary for this indication. NICE approved for this indication.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION